E0 ConsensusPreliminaryPEM unclearSystematic-ReviewPeer-reviewedReviewed
Neurological aspects of human parvovirus B19 infection: a systematic review.
Barah, Faraj, Whiteside, Sigrid, Batista, Sonia et al. · Reviews in medical virology · 2014 · DOI
Quick Summary
This review examined published cases where parvovirus B19 (a common virus) was linked to neurological problems like brain inflammation and nerve damage. Researchers found 129 documented cases in medical literature, with the majority involving brain-related symptoms. The study suggests doctors should consider B19 testing when patients have unexplained brain inflammation, and that certain treatments (immunoglobulins and steroids) may help in severe cases.
Why It Matters
This review is relevant to ME/CFS because a subset of cases (9 patients, 7%) were explicitly linked to myalgic encephalomyelitis, suggesting B19 may trigger or contribute to ME-like illness in some individuals. Understanding viral triggers for ME/CFS and improving diagnostic pathways could help identify subgroups requiring targeted treatment and clarify disease etiology.
Observed Findings
- Out of 129 documented cases, 79 (61.2%) presented with CNS manifestations
- 41 (31.8%) presented with peripheral nervous system manifestations
- 9 (7.0%) cases were linked with myalgic encephalomyelitis
- Encephalitis was the most common neurological manifestation (50/129 cases, 38.8%)
- Diagnosis relied on anti-B19 IgM antibodies and B19 DNA detection in serum or CSF
Inferred Conclusions
- Parvovirus B19 should be included in the differential diagnosis of encephalitic syndromes of unknown etiology across all age groups
- Severe B19-associated neurological cases may benefit from combined intravenous immunoglobulin and steroid therapy
- B19 may trigger neurological complications through mechanisms that warrant further investigation in controlled studies
Remaining Questions
- What is the true incidence and prevalence of B19-associated neurological manifestations in the general population?
- What are the precise pathogenic mechanisms by which B19 causes or contributes to CNS, PNS, and ME-like manifestations?
- Which clinical or immunological features predict treatment response to immunoglobulin and steroid combination therapy?
What This Study Does Not Prove
This review does not establish B19 as a direct cause of ME/CFS—it only documents cases where both conditions were reported together. The study cannot determine whether B19 triggers ME/CFS, coincidentally occurs in ME/CFS patients, or represents a distinct clinical entity. The case-report methodology cannot establish incidence rates or population-level epidemiology.
Tags
Symptom:Fatigue
Biomarker:AutoantibodiesBlood Biomarker
Phenotype:Infection-Triggered
Method Flag:Weak Case DefinitionNo ControlsExploratory OnlySmall Sample
Metadata
- DOI
- 10.1002/rmv.1782
- PMID
- 24459081
- Review status
- Editor reviewed
- Evidence level
- Higher-level evidence type — systematic reviews, meta-analyses, guidelines, or major syntheses (study type, not a quality guarantee)
- Last updated
- 12 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.